The CEO of Pfizer said people who received his Covid-19 vaccine would “probably” need a third dose within six months to a year, and then arguably an injection each year, in order to better fight against variants.
People who have received Pfizer’s vaccine against Covid-19 will “probably” need a third dose within six months to a year, then probably an injection each year, said Albert Bourla, the boss of the American pharmaceutical giant. On the same day, the director of the anti-Covid cell of the Biden administration also assured that Americans should expect to receive a booster of the vaccine, in order to protect them against variants of the coronavirus.
A third dose will likely be needed, between six months and twelve months
In statements released April 15 by CNBC, the CEO of Pfizer said: “A plausible assumption is that a third dose will likely be needed, between six months and twelve months, and from there, there will be a vaccination again every year, but all this must be confirmed ”. “On the other hand, variants will play a key role”, he added, before recalling that it is “extremely important to reduce as much as possible the number of people vulnerable to the virus”.
A scenario also considered by the Biden administration
Earlier today, the director of the anti-Covid cell of the Biden administration also assured that Americans should expect to receive a vaccine booster in order to protect them against circulating variants of the coronavirus. “We do not know everything at this stage,” admitted Dr. David Kessler, during a hearing before American parliamentarians. “We are studying the duration of the antibody response,” he said, adding that it “seems strong but it is experiencing a certain decline” and that “the variants are a challenge”. “For logistical reasons, and only for logistical reasons, I think we should consider that there may be a recall,” said David Kessler.
The Pfizer / BioNTech alliance had already announced last February to observe in a clinical study the effects of a third dose of its vaccine against the variants.
Administered in two doses, this vaccine uses – like Moderna’s – innovative messenger RNA technology, which had never before been marketed to the general public. At this stage, these two vaccines against Covid-19 are presented as being the best performing, with an efficacy of 95% for that of Pfizer / BioNTech and 94.1% for Moderna, according to clinical studies.